Latest News

Sep 19, 2022

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Aug 25, 2022

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off

Jul 25, 2022

Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
View More
image016

All News

Read in-depth news about how Sandoz is addressing healthcare needs through recent headlines.
lung-cancer-hero-image

Media Releases

Find announcements about Sandoz products, programs and company updates.

Publications

Read, download and order key company publications including annual and performance reports.

Media Library

Visit the Sandoz media resource center to view and download media resources including documents, images and videos.

Stay Up-To-Date

Subscribe to the latest news and updates from Novartis on email, RSS and more.

Media Contacts

Find contacts at Sandoz for media and journalist inquiries.

Quick links

Who We Are
What We Do
Corporate Responsibility
Working at Sandoz
site-directory

Site Directory

Sandoz today has a strong presence on all continents and is well represented in all key generics markets, allowing us to remain close to patients, doctors, healthcare providers and business partners everywhere.

Explore